{"doi":"10.1016/j.beem.2009.03.008","title":"Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results","abstract":null,"journal":"Best Practice & Research Clinical Endocrinology & Metabolism","year":2009,"id":604570,"datarank":7.014956217968583,"base_score":4.852030263919617,"endowment":4.852030263919617,"self_citation_contribution":0.7278045395879427,"citation_network_contribution":6.287151678380641,"self_endowment_contribution":0.7278045395879427,"citer_contribution":6.287151678380641,"corpus_percentile":null,"corpus_rank":null,"citation_count":127,"citer_count":119,"citers_with_citation_signal":106,"citers_with_endowment":106,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":484873,"name":"Sten Madsbad","orcid":"0000-0002-5017-1815","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results","abstract":"The GLP-1 analogues exenatide and liraglutide stimulate insulin secretion and inhibit glucagon output in a glucose-dependent manner, slow gastric emptying and decrease appetite. The injectable glucagon-like peptide-1 (GLP-1) receptor agonist exenatide significantly improves glycaemic control, with average reductions in HbA1c of about 1.0% point, fasting plasma glucose of about 1.4 mmol l(-1), and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment. The adverse effects are transient nausea and vomiting. The long-acting once-daily human GLP-1 receptor agonist liraglutide reduces HbA1c by about 1.0-2.0% point, weight by 1-3 kg and seems to have fewer gastrointestinal side effects than exenatide. The final place of the GLP-1 receptor agonists in the diabetes treatment algorithm will be clarified when we have long-term trials with cardiovascular end-points and data illustrating the effects on the progression of type 2 diabetes.","is_dataset_classified":null,"base_score":4.852030263919617,"endowment":4.852030263919617,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19748064","pmcid":null,"openalex_id":"https://openalex.org/W2045849794","authors":[],"funders":[{"funder_name":"Abbott Laboratories","grant_id":"","title":null},{"funder_name":"Novo Nordisk","grant_id":"","title":null},{"funder_name":"Sanofi","grant_id":"","title":null}],"total_grants":3,"fwci":6.7855,"citation_percentile":0.97680261,"influential_citations":0,"citation_trend":[{"year":2012,"count":11},{"year":2013,"count":12},{"year":2014,"count":18},{"year":2015,"count":10},{"year":2016,"count":12},{"year":2017,"count":7},{"year":2018,"count":5},{"year":2019,"count":6},{"year":2020,"count":4},{"year":2021,"count":2},{"year":2022,"count":4},{"year":2024,"count":4},{"year":2025,"count":4}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1521690X0900027X?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1521690X0900027X?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.beem.2009.03.008","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/19748064","host_type":"repository"},{"url":"https://researchprofiles.ku.dk/da/publications/90e56310-aabc-11df-928f-000ea68e967b","host_type":"repository"}],"fields_of_study":["Diabetes Treatment and Management","Metabolism, Diabetes, and Cancer","Pancreatic function and diabetes","Anti-Obesity Agents","Clinical Trials as Topic","Clinical Trials, Phase II as Topic","Delayed-Action Preparations","Diabetes Mellitus, Type 2","Exenatide","Glucagon-Like Peptide 1","Glucagon-Like Peptide-1 Receptor","Glycated Hemoglobin","Humans","Liraglutide","Peptides","Receptors, Glucagon","Venoms"],"mesh_terms":["Glucagon-Like Peptide-1 Receptor","Liraglutide","Exenatide","Clinical Trials as Topic","Delayed-Action Preparations","Diabetes Mellitus, Type 2","Glycated Hemoglobin","Humans","Peptides","Venoms","Clinical Trials, Phase II as Topic","Receptors, Glucagon","Anti-Obesity Agents","Glucagon-Like Peptide 1"],"keywords":["Exenatide","Liraglutide","Glucagon-like peptide 1 receptor","Incretin","Type 2 diabetes","Medicine","Endocrinology","Agonist","Internal medicine","Gastric emptying","Nausea","Glucagon-like peptide-1","Vildagliptin","Weight loss","Diabetes mellitus","Lixisenatide","Pharmacology","Receptor","Obesity","Stomach"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T00:26:02.576224Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}